ABSTRACT
PURPOSE: To present a single-center experience on pituitary tumor apoplexy and a review of literature focusing on predisposing and precipitating factors. METHODS: Clinical presentation of our series of cases. Contemporary published literature is also reviewed. RESULTS: The definition of this syndrome has not been consistent although now the majority of authors agree to definite it as an acute condition caused by hemorrhage or infarction of a pre-existing pituitary adenoma. Different predisposing and precipitating factors have been described in literature; among these antithrombotic and anticoagulant drugs, seem to play relevant roles. The clinical cases observed in our clinic confirm these data and suggest a probable association between elderly patients taking anticoagulant therapy and pituitary apoplexy adenoma. CONCLUSION: Pituitary tumor apoplexy remains a challenging disease in relation to difficulties in correct diagnosis and thus in appropriate treatment. Antithrombotic/anticoagulant therapy may have an important role as precipitating factor. When a pituitary disorder is known, great care should be taken in the prescription of anticoagulant therapy.
Subject(s)
Pituitary Apoplexy/diagnosis , Pituitary Apoplexy/therapy , Clinical Trials as Topic , HumansABSTRACT
Establishing a pharmacologic model of the memory deficits of Alzheimer's disease could be an important tool in understanding how memory fails. We examined the combined effects of the muscarinic antagonist scopolamine and the nicotinic antagonist mecamylamine in eight normal elderly volunteers (age 61.9 +/- 8.3 yrs, SD). Each received four separate drug challenges (scopolamine (0.4 mg i.v.), mecamylamine (0.2 mg/kg up to 15 mg PO), mecamylamine + scopolamine, and placebo). There was a trend toward increased impairment in explicit memory for the mecamylamine + scopolamine condition as compared to scopolamine alone. Increased impairment was also seen for the mecamylamine + scopolamine condition as compared to scopolamine alone in selected behavioral ratings. Pupil size increased when mecamylamine was added to scopolamine, while systolic blood pressure and pulse changed in concordance with ganglionic blockade. These data together with previous brain-imaging results suggest that this muscarinic-nicotinic drug combination may better model Alzheimer's disease than either drug alone.
Subject(s)
Behavior/drug effects , Cognition/drug effects , Mecamylamine/pharmacology , Muscarinic Antagonists/pharmacology , Nicotinic Antagonists/pharmacology , Scopolamine/pharmacology , Aged , Alzheimer Disease/physiopathology , Blood Pressure/drug effects , Brief Psychiatric Rating Scale , Drug Synergism , Female , Heart Rate/drug effects , Humans , Learning/drug effects , Male , Memory/drug effects , Middle Aged , Pupil/drug effects , Reaction Time/drug effectsABSTRACT
BACKGROUND: There is evidence from animal and human experiments that learning and memory come under the separate influence of both cholinergic and serotonergic pathways. We were interested in learning whether serotonergic drugs could attenuate or exacerbate the memory-impairing effects of anticholinergic blockade in humans. METHODS: The selective serotonin 5-HT3 receptor antagonist ondansetron (0.15 mg/kg i.v.) and the serotonergic agent m-chlorophenylpiperazine (m-CPP; 0.08 mg/kg i.v.) were administered in combination with the anticholinergic agent scopolamine (0.4 mg PO) and compared to scopolamine alone in 10 young, healthy volunteers. Testing occurred on three separate days. RESULTS: As expected, i.v. administration of scopolamine induced significant impairments in episodic memory and processing speed; however, these scopolamine-induced cognitive deficits were not attenuated by pretreatment with i.v. ondansetron (0.15 mg/kg), nor were they exacerbated by administration of i.v. m-CPP (0.8 mg/kg) in addition to scopolamine; however, administration of i.v. m-CPP was followed by a significant increase of self-rated functional impairment, altered self-reality, and dysphoria ratings, and scopolamine's effect on pupil size was potentiated. CONCLUSIONS: Together, these results suggest that in young, healthy volunteers scopolamine-induced changes of cognitive performance are only minimally modulated by the serotonergic effects on ondansetron and m-CPP. Further studies with older controls are needed to test whether these findings may be influenced by age.
Subject(s)
Behavior/drug effects , Cognition/drug effects , Ondansetron/pharmacology , Parasympatholytics/pharmacology , Piperazines/pharmacology , Scopolamine/antagonists & inhibitors , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology , Adult , Female , Humans , Male , Memory/drug effects , Psychomotor Performance/drug effects , Pupil/drug effects , Reaction Time/drug effects , Reference Values , Scopolamine/pharmacologySubject(s)
Alzheimer Disease/diagnosis , Dementia/diagnosis , Depressive Disorder/diagnosis , Neuropsychological Tests , Personality Assessment , Aged , Alzheimer Disease/psychology , Anxiety Disorders/diagnosis , Anxiety Disorders/psychology , Arousal , Dementia/psychology , Depressive Disorder/psychology , Diagnosis, Differential , Geriatric Assessment , HumansABSTRACT
Thyrotropin-releasing hormone (TRH) produces a marked pressor effect, which may be mediated by central cholinergic neurons, which in turn enhance sympathetic nervous system activity. In this study, 22 subjects (10 patients with Alzheimer's disease and 12 elderly controls) were administered IV scopolamine or placebo prior to administration of IV high-dose TRH (0.5 mg/kg). Systolic blood pressure was less on the day scopolamine was administered prior to TRH administration, as compared with placebo (F[1,20] = 6.12, p < 0.02). Results indicate that the pressor effect of TRH is attenuated by scopolamine, indicating a role of the cholinergic system in this response in humans.
Subject(s)
Blood Pressure/drug effects , Scopolamine/pharmacology , Thyrotropin-Releasing Hormone/physiology , Aged , Alzheimer Disease/blood , Alzheimer Disease/drug therapy , Alzheimer Disease/physiopathology , Dose-Response Relationship, Drug , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Male , Methoxyhydroxyphenylglycol/blood , Middle AgedABSTRACT
Deficient immunoregulation has been postulated to play a role in the pathogenesis of Alzheimer's dementia. Recently, lymphopenia was reported to be more prevalent in Alzheimer patients than in control subjects. In addition, a decreasing number of total lymphocytes was found to be significantly correlated with increasing severity of dementia. In an attempt to replicate these findings, we studied 55 Alzheimer patients and 41 healthy controls of comparable age and gender, but found no significant difference in the distribution of total lymphocytes between these groups. Furthermore, total lymphocytes were not significantly correlated with dementia severity. Our findings, therefore, do not lend further support to an immune hypothesis for Alzheimer's dementia.
Subject(s)
Alzheimer Disease/immunology , Leukocyte Count , Lymphocytes/immunology , Adult , Aged , Aged, 80 and over , Female , Humans , Hydrocortisone/blood , Male , Mental Status Schedule , Middle AgedSubject(s)
Alzheimer Disease/drug therapy , Depressive Disorder/chemically induced , Physostigmine/therapeutic use , Alzheimer Disease/diagnosis , Alzheimer Disease/psychology , Depressive Disorder/diagnosis , Depressive Disorder/psychology , Female , Humans , Middle Aged , Physostigmine/adverse effects , Physostigmine/pharmacology , Psychiatric Status Rating ScalesABSTRACT
A perfusion culture system has been developed for 31P NMR study of human uveal melanoma metabolism by adapting the Vitafiber I cartridge system (Amicon). 31P NMR spectra collected weekly during periods of up to 10 weeks demonstrated increasing levels of phosphorus metabolites as the anchorage-dependent cells grew to tissue-like density.
Subject(s)
Magnetic Resonance Spectroscopy/methods , Melanoma/analysis , Uveal Neoplasms/analysis , Equipment Design , Humans , In Vitro Techniques , Melanoma/ultrastructure , Perfusion/instrumentation , Phosphorus , Tumor Cells, Cultured , Uveal Neoplasms/ultrastructureABSTRACT
Clinical evaluation of uveal melanomas by nuclear magnetic resonance (NMR) techniques depends on ascertaining how these tumors characteristically appear in NMR images and spectra. The authors have determined NMR characteristics of suspected uveal melanomas by phosphorus-31 (31P) NMR spectroscopy of freshly enucleated human eyes. Nuclear magnetic resonance examination was performed at 8.45 Tesla within 90 minutes after enucleation. Enucleated eyes were maintained at 4 degrees C in tissue culture medium during the 30 minutes required for transport. Nuclear magnetic resonance spectra were obtained within 10 minutes, a clinically acceptable time, using a two-turn 31P surface coil. Spectral parameters included 10-kHz spectral width, 1024 data points, and 0.5-second recycle delay. Phosphorus-31 NMR spectroscopy allowed differentiation of choroidal melanomas from normal ocular structures. Differentiating features include significant peaks in tumor spectra due to the phosphodiesters glycerol 3-phosphoryl ethanolamine (GPE) and glycerol 3-phosphorylcholine (GPC), and the phosphomonoesters phosphorylethanolamine (PE) and phosphorylcholine (PC). These preliminary data are encouraging and suggest that clinical trials at the lower magnetic field strengths available in NMR imaging systems seem feasible and warrant investigation.
Subject(s)
Magnetic Resonance Spectroscopy , Melanoma/diagnosis , Phosphorus , Uveal Neoplasms/diagnosis , Choroid Neoplasms/diagnosis , Choroid Neoplasms/pathology , Eye/pathology , Eye Enucleation , Fundus Oculi , Humans , Magnetic Resonance Spectroscopy/methods , Melanoma/pathology , Uveal Neoplasms/pathologyABSTRACT
Evidence from animal and human studies suggests that procaine hydrochloride may selectively activate limbic system structures and suppress neocortical structures. We administered a series of intravenous bolus doses of procaine hydrochloride to 31 subjects (7 with affective disorders, 17 with borderline personality disorder, and 7 healthy normal volunteers). Dose-related cognitive and sensory distortions and illusions were observed; affective experiences ranged widely from euphoric to dysphoric. Topographic electroencephalogram (EEG) analysis indicated selective increases in fast activity (26-45 Hz) over the temporal lobes; the degree of increase in this activity correlated with degree of dysphoria experienced. Procaine was associated with increases in secretion of cortisol, adrenocorticotrophic hormone (ACTH), and prolactin, but not with growth hormone. These preliminary data are consistent with the possibility that procaine might serve as a clinically useful probe of psychosensory, affective, electrophysiological, and endocrine effects referable to the limbic system.
Subject(s)
Borderline Personality Disorder/physiopathology , Limbic System/drug effects , Mood Disorders/physiopathology , Personality Disorders/physiopathology , Procaine/pharmacology , Adrenocorticotropic Hormone/metabolism , Adult , Cognition/drug effects , Electroencephalography , Endocrine Glands/drug effects , Humans , Hydrocortisone/metabolism , Memory/drug effects , Perceptual Distortion/drug effects , Prolactin/metabolismABSTRACT
Motor activity in 19 depressed patients treated with carbamazepine was assessed using self-contained monitors worn on the wrist. Those whose depression improved demonstrated significant increases in motor activity. Nonresponders as a group did not show decreased motor activity, suggesting that carbamazepine was not producing sedation or hypoactivity at clinically relevant doses. Activity counts were negatively correlated with ratings of global severity of depression on the Bunney-Hamburg Scale and with degree of motor retardation rated on the BPRS during treatment. The selective increases in motor activity in those who improved are consistent with psychomotor changes related to amelioration of depression.
Subject(s)
Bipolar Disorder/drug therapy , Carbamazepine/therapeutic use , Depressive Disorder/drug therapy , Motor Activity/drug effects , Psychotic Disorders/drug therapy , Adult , Bipolar Disorder/psychology , Depressive Disorder/psychology , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Psychotic Disorders/psychologyABSTRACT
The effects of disulfiram on depression and anxiety were examined. In a 3-week double-blind study, 40 inpatients in al alcohol rehabilitation unit (ARU) were randomly assigned to receive placebo, 250 mg/day of disulfiram or 500 mg/day of disulfiram. During their first week in the ARU and prior to beginning medications, all subjects were administered the Zung self-rating depression scale, the Hamilton observer rating scale for depression, the Zung self-rating scale for anxiety and the Hamilton observer rating scale for anxiety. All subjects were rescored on these instruments at the end of their third week in the ARU. Three psychiatrists, blind to the medication condition, sequentially scored the Hamilton items. To evaluate intergroup differences at baseline as well as changes in scale scores during the 3 weeks, scale scores were subjected to analyses of variance. No statistically significant effect attributable to disulfiram was found but significant changes due to a time effect were noted.